ID   GBB1_HUMAN              Reviewed;         340 AA.
AC   P62873; B1AJZ7; P04697; P04901; Q1RMY8;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   18-JUL-2018, entry version 163.
DE   RecName: Full=Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1;
DE   AltName: Full=Transducin beta chain 1;
GN   Name=GNB1 {ECO:0000312|HGNC:HGNC:4396};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=3095147; DOI=10.1016/0014-5793(86)81486-7;
RA   Codina J., Stengel D., Woo S.L.C., Birnbaumer L.;
RT   "Beta-subunits of the human liver Gs/Gi signal-transducing proteins
RT   and those of bovine retinal rod cell transducin are identical.";
RL   FEBS Lett. 207:187-192(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain, Muscle, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-15; 58-89; 284-301 AND 305-314, CLEAVAGE OF
RP   INITIATOR METHIONINE, ACETYLATION AT SER-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=B-cell lymphoma, and Melanoma;
RA   Bienvenut W.V., Quadroni M.;
RL   Submitted (JUL-2005) to UniProtKB.
RN   [9]
RP   PROTEIN SEQUENCE OF 2-8; 69-78 AND 90-96, CLEAVAGE OF INITIATOR
RP   METHIONINE, ACETYLATION AT SER-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Ovarian carcinoma;
RA   Bienvenut W.V., Lilla S., von Kriegsheim A., Lempens A., Kolch W.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [10]
RP   PROTEIN SEQUENCE OF 23-42; 58-78; 138-150; 198-209 AND 315-337, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Fetal brain cortex;
RA   Lubec G., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [11]
RP   INTERACTION WITH ARHGEF18.
RX   PubMed=14512443; DOI=10.1161/01.RES.0000097607.14733.0C;
RA   Niu J., Profirovic J., Pan H., Vaiskunaite R., Voyno-Yasenetskaya T.;
RT   "G Protein betagamma subunits stimulate p114RhoGEF, a guanine
RT   nucleotide exchange factor for RhoA and Rac1: regulation of cell shape
RT   and reactive oxygen species production.";
RL   Circ. Res. 93:848-856(2003).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [13]
RP   INTERACTION WITH RASD2.
RX   PubMed=19255495; DOI=10.1159/000204075;
RA   Hill C., Goddard A., Ladds G., Davey J.;
RT   "The cationic region of Rhes mediates its interactions with specific
RT   Gbeta subunits.";
RL   Cell. Physiol. Biochem. 23:1-8(2009).
RN   [14]
RP   INTERACTION WITH ARHGEF5.
RX   PubMed=19713215; DOI=10.1074/jbc.M109.047282;
RA   Wang Z., Kumamoto Y., Wang P., Gan X., Lehmann D., Smrcka A.V.,
RA   Cohn L., Iwasaki A., Li L., Wu D.;
RT   "Regulation of immature dendritic cell migration by RhoA guanine
RT   nucleotide exchange factor Arhgef5.";
RL   J. Biol. Chem. 284:28599-28606(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [19]
RP   INVOLVEMENT IN MRD42, AND VARIANTS MRD42 GLU-76; GLY-76; SER-77;
RP   ARG-78; ASN-80; THR-80; PRO-95; VAL-101 AND THR-326.
RX   PubMed=27108799; DOI=10.1016/j.ajhg.2016.03.011;
RG   University of Washington Center for Mendelian Genomics;
RA   Petrovski S., Kuery S., Myers C.T., Anyane-Yeboa K., Cogne B.,
RA   Bialer M., Xia F., Hemati P., Riviello J., Mehaffey M., Besnard T.,
RA   Becraft E., Wadley A., Politi A.R., Colombo S., Zhu X., Ren Z.,
RA   Andrews I., Dudding-Byth T., Schneider A.L., Wallace G., Rosen A.B.,
RA   Schelley S., Enns G.M., Corre P., Dalton J., Mercier S., Latypova X.,
RA   Schmitt S., Guzman E., Moore C., Bier L., Heinzen E.L.,
RA   Karachunski P., Shur N., Grebe T., Basinger A., Nguyen J.M.,
RA   Bezieau S., Wierenga K., Bernstein J.A., Scheffer I.E.,
RA   Rosenfeld J.A., Mefford H.C., Isidor B., Goldstein D.B.;
RT   "Germline de novo mutations in GNB1 cause severe neurodevelopmental
RT   disability, hypotonia, and seizures.";
RL   Am. J. Hum. Genet. 98:1001-1010(2016).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) IN COMPLEX WITH GNG2.
RX   PubMed=18611381; DOI=10.1016/j.str.2008.04.010;
RA   Johnston C.A., Kimple A.J., Giguere P.M., Siderovski D.P.;
RT   "Structure of the parathyroid hormone receptor C terminus bound to the
RT   G-protein dimer Gbeta1gamma2.";
RL   Structure 16:1086-1094(2008).
RN   [21]
RP   ERRATUM, AND RETRACTION.
RX   PubMed=21827955; DOI=10.1016/j.str.2011.07.010;
RA   Johnston C.A., Kimple A.J., Giguere P.M., Siderovski D.P.;
RL   Structure 19:1200-1200(2011).
RN   [22]
RP   CHARACTERIZATION VARIANTS MRD42 ASN-80 AND THR-80.
RX   PubMed=25485910; DOI=10.1038/nm.3751;
RA   Yoda A., Adelmant G., Tamburini J., Chapuy B., Shindoh N., Yoda Y.,
RA   Weigert O., Kopp N., Wu S.C., Kim S.S., Liu H., Tivey T.,
RA   Christie A.L., Elpek K.G., Card J., Gritsman K., Gotlib J.,
RA   Deininger M.W., Makishima H., Turley S.J., Javidi-Sharifi N.,
RA   Maciejewski J.P., Jaiswal S., Ebert B.L., Rodig S.J., Tyner J.W.,
RA   Marto J.A., Weinstock D.M., Lane A.A.;
RT   "Mutations in G protein beta subunits promote transformation and
RT   kinase inhibitor resistance.";
RL   Nat. Med. 21:71-75(2015).
RN   [23]
RP   VARIANT MRD42 GLY-118.
RX   PubMed=27668284; DOI=10.1212/NXG.0000000000000106;
RA   Steinruecke S., Lohmann K., Domingo A., Rolfs A., Baeumer T.,
RA   Spiegler J., Hartmann C., Muenchau A.;
RT   "Novel GNB1 missense mutation in a patient with generalized dystonia,
RT   hypotonia, and intellectual disability.";
RL   Neurol. Genet. 2:E106-E106(2016).
RN   [24]
RP   VARIANTS MRD42 PHE-30; GLY-52; VAL-64; ARG-91; THR-92; SER-94; LEU-96;
RP   THR-106; GLY-118 AND GLN-337, AND CHARACTERIZATION OF VARIANTS MRD42
RP   PHE-30; GLY-52; VAL-64; ARG-91; THR-92; SER-94; LEU-96; THR-106;
RP   GLY-118 AND GLN-337.
RX   PubMed=28087732; DOI=10.1093/hmg/ddx018;
RA   Lohmann K., Masuho I., Patil D.N., Baumann H., Hebert E.,
RA   Steinruecke S., Trujillano D., Skamangas N.K., Dobricic V.,
RA   Huening I., Gillessen-Kaesbach G., Westenberger A.,
RA   Savic-Pavicevic D., Muenchau A., Oprea G., Klein C., Rolfs A.,
RA   Martemyanov K.A.;
RT   "Novel GNB1 mutations disrupt assembly and function of G protein
RT   heterotrimers and cause global developmental delay in humans.";
RL   Hum. Mol. Genet. 26:1078-1086(2017).
CC   -!- FUNCTION: Guanine nucleotide-binding proteins (G proteins) are
CC       involved as a modulator or transducer in various transmembrane
CC       signaling systems. The beta and gamma chains are required for the
CC       GTPase activity, for replacement of GDP by GTP, and for G protein-
CC       effector interaction.
CC   -!- SUBUNIT: G proteins are composed of 3 units, alpha, beta and
CC       gamma. Interacts with ARHGEF18 and RASD2 (PubMed:14512443,
CC       PubMed:19255495). The heterodimer formed by GNB1 and GNG2
CC       interacts with ARHGEF5 (PubMed:19713215).
CC       {ECO:0000269|PubMed:14512443, ECO:0000269|PubMed:19255495,
CC       ECO:0000269|PubMed:19713215}.
CC   -!- INTERACTION:
CC       P59768:GNG2; NbExp=4; IntAct=EBI-357130, EBI-602681;
CC       P19878:NCF2; NbExp=2; IntAct=EBI-357130, EBI-489611;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P62873-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P62873-2; Sequence=VSP_055232;
CC         Note=No experimental confirmation available.;
CC   -!- PTM: Phosphorylation at His-266 by NDKB contributes to G protein
CC       activation by increasing the high energetic phosphate transfer
CC       onto GDP. {ECO:0000250}.
CC   -!- DISEASE: Mental retardation, autosomal dominant 42 (MRD42)
CC       [MIM:616973]: A form of mental retardation, a disorder
CC       characterized by significantly below average general intellectual
CC       functioning associated with impairments in adaptive behavior and
CC       manifested during the developmental period. MRD42 patients
CC       manifest global developmental delay commonly accompanied by
CC       hypotonia, seizures of various types, ophthalmological
CC       manifestations, and poor growth. {ECO:0000269|PubMed:25485910,
CC       ECO:0000269|PubMed:27108799, ECO:0000269|PubMed:27668284,
CC       ECO:0000269|PubMed:28087732}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the WD repeat G protein beta family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; X04526; CAA28207.1; -; mRNA.
DR   EMBL; AF501882; AAM15918.1; -; mRNA.
DR   EMBL; BT007305; AAP35969.1; -; mRNA.
DR   EMBL; CR456784; CAG33065.1; -; mRNA.
DR   EMBL; AL031282; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL109917; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471183; EAW56147.1; -; Genomic_DNA.
DR   EMBL; BC004186; AAH04186.1; -; mRNA.
DR   EMBL; BC005888; AAH05888.1; -; mRNA.
DR   EMBL; BC008991; AAH08991.1; -; mRNA.
DR   EMBL; BC114618; AAI14619.1; -; mRNA.
DR   EMBL; M36430; AAA63265.1; -; mRNA.
DR   CCDS; CCDS34.1; -. [P62873-1]
DR   PIR; A24853; RGHUB1.
DR   RefSeq; NP_001269467.1; NM_001282538.1.
DR   RefSeq; NP_001269468.1; NM_001282539.1. [P62873-1]
DR   RefSeq; NP_002065.1; NM_002074.4. [P62873-1]
DR   RefSeq; XP_016856548.1; XM_017001059.1. [P62873-1]
DR   RefSeq; XP_016856549.1; XM_017001060.1. [P62873-1]
DR   RefSeq; XP_016856550.1; XM_017001061.1. [P62873-1]
DR   UniGene; Hs.430425; -.
DR   UniGene; Hs.721030; -.
DR   PDB; 4KFM; X-ray; 3.45 A; B=1-340.
DR   PDB; 4PNK; X-ray; 2.56 A; B=1-340.
DR   PDB; 5HE0; X-ray; 2.56 A; B=2-340.
DR   PDB; 5HE1; X-ray; 3.15 A; B=2-340.
DR   PDB; 5HE2; X-ray; 2.79 A; B=2-340.
DR   PDB; 5HE3; X-ray; 2.74 A; B=2-340.
DR   PDB; 5UKK; X-ray; 2.60 A; B=2-340.
DR   PDB; 5UKL; X-ray; 2.15 A; B=2-340.
DR   PDB; 5UKM; X-ray; 3.03 A; B=2-340.
DR   PDB; 5UZ7; EM; 4.10 A; B=2-340.
DR   PDB; 6B3J; EM; 3.30 A; B=2-340.
DR   PDB; 6GDG; EM; 4.11 A; B=2-340.
DR   PDBsum; 4KFM; -.
DR   PDBsum; 4PNK; -.
DR   PDBsum; 5HE0; -.
DR   PDBsum; 5HE1; -.
DR   PDBsum; 5HE2; -.
DR   PDBsum; 5HE3; -.
DR   PDBsum; 5UKK; -.
DR   PDBsum; 5UKL; -.
DR   PDBsum; 5UKM; -.
DR   PDBsum; 5UZ7; -.
DR   PDBsum; 6B3J; -.
DR   PDBsum; 6GDG; -.
DR   ProteinModelPortal; P62873; -.
DR   SMR; P62873; -.
DR   BioGrid; 109044; 109.
DR   CORUM; P62873; -.
DR   DIP; DIP-599N; -.
DR   IntAct; P62873; 53.
DR   MINT; P62873; -.
DR   STRING; 9606.ENSP00000367869; -.
DR   ChEMBL; CHEMBL3883319; -.
DR   TCDB; 8.A.92.1.1; the g-protein AlphaBetaGama complex (gpc) family.
DR   iPTMnet; P62873; -.
DR   PhosphoSitePlus; P62873; -.
DR   SwissPalm; P62873; -.
DR   DMDM; 51317302; -.
DR   OGP; P62873; -.
DR   REPRODUCTION-2DPAGE; IPI00026268; -.
DR   EPD; P62873; -.
DR   MaxQB; P62873; -.
DR   PaxDb; P62873; -.
DR   PeptideAtlas; P62873; -.
DR   PRIDE; P62873; -.
DR   ProteomicsDB; 57441; -.
DR   DNASU; 2782; -.
DR   Ensembl; ENST00000378609; ENSP00000367872; ENSG00000078369. [P62873-1]
DR   Ensembl; ENST00000610897; ENSP00000481878; ENSG00000078369. [P62873-1]
DR   GeneID; 2782; -.
DR   KEGG; hsa:2782; -.
DR   UCSC; uc001aif.5; human. [P62873-1]
DR   CTD; 2782; -.
DR   DisGeNET; 2782; -.
DR   EuPathDB; HostDB:ENSG00000078369.17; -.
DR   GeneCards; GNB1; -.
DR   HGNC; HGNC:4396; GNB1.
DR   HPA; HPA040736; -.
DR   MalaCards; GNB1; -.
DR   MIM; 139380; gene.
DR   MIM; 616973; phenotype.
DR   neXtProt; NX_P62873; -.
DR   OpenTargets; ENSG00000078369; -.
DR   PharmGKB; PA28776; -.
DR   eggNOG; KOG0286; Eukaryota.
DR   eggNOG; ENOG410XQUX; LUCA.
DR   GeneTree; ENSGT00760000119239; -.
DR   HOGENOM; HOG000176356; -.
DR   HOVERGEN; HBG000188; -.
DR   InParanoid; P62873; -.
DR   KO; K04536; -.
DR   OMA; TCNVWDT; -.
DR   OrthoDB; EOG091G0A7T; -.
DR   PhylomeDB; P62873; -.
DR   TreeFam; TF106149; -.
DR   Reactome; R-HSA-1296041; Activation of G protein gated Potassium channels.
DR   Reactome; R-HSA-163359; Glucagon signaling in metabolic regulation.
DR   Reactome; R-HSA-202040; G-protein activation.
DR   Reactome; R-HSA-2485179; Activation of the phototransduction cascade.
DR   Reactome; R-HSA-2514859; Inactivation, recovery and regulation of the phototransduction cascade.
DR   Reactome; R-HSA-381676; Glucagon-like Peptide-1 (GLP1) regulates insulin secretion.
DR   Reactome; R-HSA-381753; Olfactory Signaling Pathway.
DR   Reactome; R-HSA-392170; ADP signalling through P2Y purinoceptor 12.
DR   Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma.
DR   Reactome; R-HSA-392851; Prostacyclin signalling through prostacyclin receptor.
DR   Reactome; R-HSA-400042; Adrenaline,noradrenaline inhibits insulin secretion.
DR   Reactome; R-HSA-4086398; Ca2+ pathway.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-416482; G alpha (12/13) signalling events.
DR   Reactome; R-HSA-418217; G beta:gamma signalling through PLC beta.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-418592; ADP signalling through P2Y purinoceptor 1.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-418597; G alpha (z) signalling events.
DR   Reactome; R-HSA-420092; Glucagon-type ligand receptors.
DR   Reactome; R-HSA-428930; Thromboxane signalling through TP receptor.
DR   Reactome; R-HSA-432040; Vasopressin regulates renal water homeostasis via Aquaporins.
DR   Reactome; R-HSA-456926; Thrombin signalling through proteinase activated receptors (PARs).
DR   Reactome; R-HSA-500657; Presynaptic function of Kainate receptors.
DR   Reactome; R-HSA-6814122; Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding.
DR   Reactome; R-HSA-997272; Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits.
DR   SignaLink; P62873; -.
DR   SIGNOR; P62873; -.
DR   ChiTaRS; GNB1; human.
DR   EvolutionaryTrace; P62873; -.
DR   GeneWiki; GNB1; -.
DR   GenomeRNAi; 2782; -.
DR   PRO; PR:P62873; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000078369; -.
DR   CleanEx; HS_GNB1; -.
DR   ExpressionAtlas; P62873; baseline and differential.
DR   Genevisible; P62873; HS.
DR   GO; GO:0044297; C:cell body; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:1903561; C:extracellular vesicle; HDA:UniProtKB.
DR   GO; GO:0005834; C:heterotrimeric G-protein complex; IDA:MGI.
DR   GO; GO:0005622; C:intracellular; ISS:BHF-UCL.
DR   GO; GO:0005765; C:lysosomal membrane; HDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; ISS:BHF-UCL.
DR   GO; GO:0043209; C:myelin sheath; IEA:Ensembl.
DR   GO; GO:0097381; C:photoreceptor disc membrane; TAS:Reactome.
DR   GO; GO:0001917; C:photoreceptor inner segment; IEA:Ensembl.
DR   GO; GO:0042622; C:photoreceptor outer segment membrane; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0047391; F:alkylglycerophosphoethanolamine phosphodiesterase activity; IEA:Ensembl.
DR   GO; GO:0003924; F:GTPase activity; IDA:MGI.
DR   GO; GO:0051020; F:GTPase binding; IPI:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:MGI.
DR   GO; GO:0030507; F:spectrin binding; IEA:Ensembl.
DR   GO; GO:0031702; F:type 1 angiotensin receptor binding; IEA:Ensembl.
DR   GO; GO:0007191; P:adenylate cyclase-activating dopamine receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0010659; P:cardiac muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0008283; P:cell proliferation; IEA:Ensembl.
DR   GO; GO:0071870; P:cellular response to catecholamine stimulus; ISS:BHF-UCL.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0071380; P:cellular response to prostaglandin E stimulus; ISS:BHF-UCL.
DR   GO; GO:0007213; P:G-protein coupled acetylcholine receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007200; P:phospholipase C-activating G-protein coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IEA:Ensembl.
DR   GO; GO:0006457; P:protein folding; TAS:Reactome.
DR   GO; GO:0070208; P:protein heterotrimerization; IEA:Ensembl.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:ProtInc.
DR   GO; GO:0060041; P:retina development in camera-type eye; IEA:Ensembl.
DR   GO; GO:0016056; P:rhodopsin mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0050909; P:sensory perception of taste; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007223; P:Wnt signaling pathway, calcium modulating pathway; TAS:Reactome.
DR   Gene3D; 2.130.10.10; -; 1.
DR   InterPro; IPR020472; G-protein_beta_WD-40_rep.
DR   InterPro; IPR001632; Gprotein_B.
DR   InterPro; IPR016346; Guanine_nucleotide-bd_bsu.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf.
DR   InterPro; IPR001680; WD40_repeat.
DR   InterPro; IPR019775; WD40_repeat_CS.
DR   InterPro; IPR017986; WD40_repeat_dom.
DR   InterPro; IPR036322; WD40_repeat_dom_sf.
DR   PANTHER; PTHR19850; PTHR19850; 1.
DR   Pfam; PF00400; WD40; 7.
DR   PRINTS; PR00319; GPROTEINB.
DR   PRINTS; PR00320; GPROTEINBRPT.
DR   SMART; SM00320; WD40; 7.
DR   SUPFAM; SSF50978; SSF50978; 1.
DR   PROSITE; PS00678; WD_REPEATS_1; 3.
DR   PROSITE; PS50082; WD_REPEATS_2; 6.
DR   PROSITE; PS50294; WD_REPEATS_REGION; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Mental retardation;
KW   Phosphoprotein; Reference proteome; Repeat; Transducer; WD repeat.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:25944712,
FT                                ECO:0000269|Ref.8, ECO:0000269|Ref.9}.
FT   CHAIN         2    340       Guanine nucleotide-binding protein
FT                                G(I)/G(S)/G(T) subunit beta-1.
FT                                /FTId=PRO_0000127687.
FT   REPEAT       53     83       WD 1.
FT   REPEAT       95    125       WD 2.
FT   REPEAT      141    170       WD 3.
FT   REPEAT      182    212       WD 4.
FT   REPEAT      224    254       WD 5.
FT   REPEAT      268    298       WD 6.
FT   REPEAT      310    340       WD 7.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:25944712,
FT                                ECO:0000269|Ref.8, ECO:0000269|Ref.9}.
FT   MOD_RES       2      2       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     266    266       Phosphohistidine.
FT                                {ECO:0000250|UniProtKB:P62871}.
FT   VAR_SEQ     329    340       TGSWDSFLKIWN -> SVLG (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_055232.
FT   VARIANT      30     30       L -> F (in MRD42; unknown pathological
FT                                significance; no effect on protein
FT                                abundance; no effect on complex formation
FT                                with gamma subunit; no effect on trimer
FT                                formation with alpha and gamma subunits;
FT                                no effect on receptor-driven G protein
FT                                activation; dbSNP:rs764997309).
FT                                {ECO:0000269|PubMed:28087732}.
FT                                /FTId=VAR_078279.
FT   VARIANT      52     52       R -> G (in MRD42; decreases receptor-
FT                                driven G protein activation; no effect on
FT                                protein abundance; no effect on complex
FT                                formation with gamma subunit; decreases
FT                                trimer formation with alpha and gamma
FT                                subunit). {ECO:0000269|PubMed:28087732}.
FT                                /FTId=VAR_078280.
FT   VARIANT      64     64       G -> V (in MRD42; decreases receptor-
FT                                driven G protein activation; decreases
FT                                protein abundance; decreases complex
FT                                formation with gamma subunit; decreases
FT                                trimer formation with alpha and gamma
FT                                subunit). {ECO:0000269|PubMed:28087732}.
FT                                /FTId=VAR_078281.
FT   VARIANT      76     76       D -> E (in MRD42; dbSNP:rs869312822).
FT                                {ECO:0000269|PubMed:27108799}.
FT                                /FTId=VAR_076644.
FT   VARIANT      76     76       D -> G (in MRD42; dbSNP:rs869312821).
FT                                {ECO:0000269|PubMed:27108799}.
FT                                /FTId=VAR_076643.
FT   VARIANT      77     77       G -> S (in MRD42; dbSNP:rs758432471).
FT                                {ECO:0000269|PubMed:27108799}.
FT                                /FTId=VAR_076645.
FT   VARIANT      78     78       K -> R (in MRD42; dbSNP:rs869312823).
FT                                {ECO:0000269|PubMed:27108799}.
FT                                /FTId=VAR_076646.
FT   VARIANT      80     80       I -> N (in MRD42; also found in patients
FT                                with acute lymphoblastic T-cell leukemia;
FT                                reduces interaction with GNAI2, GNAI3,
FT                                GNA13 and GNA11; induces activation of
FT                                PI3K-AKT-mTOR and MAPK pathways;
FT                                dbSNP:rs752746786).
FT                                {ECO:0000269|PubMed:25485910,
FT                                ECO:0000269|PubMed:27108799}.
FT                                /FTId=VAR_076647.
FT   VARIANT      80     80       I -> T (in MRD42; also found in patient
FT                                with hematologic malignancies; reduces
FT                                interaction with GNAI2, GNAI3, GNA13 and
FT                                GNA11; induces activation of PI3K-AKT-
FT                                mTOR and MAPK pathways;
FT                                dbSNP:rs752746786).
FT                                {ECO:0000269|PubMed:25485910,
FT                                ECO:0000269|PubMed:27108799}.
FT                                /FTId=VAR_076648.
FT   VARIANT      91     91       H -> R (in MRD42; unknown pathological
FT                                significance; no effect on protein
FT                                abundance; no effect on complex formation
FT                                with gamma subunit; no effect on trimer
FT                                formation with apha and gamma subunits;
FT                                no effect on receptor-driven G protein
FT                                activation).
FT                                {ECO:0000269|PubMed:28087732}.
FT                                /FTId=VAR_078282.
FT   VARIANT      92     92       A -> T (in MRD42; decreases receptor-
FT                                driven G protein activation; increases
FT                                trimer formation with alpha and gamma
FT                                subunits; no effect on protein abundance;
FT                                no effect on complex formation with gamma
FT                                subunit). {ECO:0000269|PubMed:28087732}.
FT                                /FTId=VAR_078283.
FT   VARIANT      94     94       P -> S (in MRD42; decreases receptor-
FT                                driven G protein activation; decreases
FT                                trimer formation with alpha and gamma
FT                                subunit; no effect on protein
FT                                abundance;no effect on complex formation
FT                                with gamma subunit).
FT                                {ECO:0000269|PubMed:28087732}.
FT                                /FTId=VAR_078284.
FT   VARIANT      95     95       L -> P (in MRD42; dbSNP:rs869312824).
FT                                {ECO:0000269|PubMed:27108799}.
FT                                /FTId=VAR_076649.
FT   VARIANT      96     96       R -> L (in MRD42; decreases receptor-
FT                                driven G protein activation; decreases
FT                                trimer formation with alpha and gamma
FT                                subunit; no effect on protein abundance;
FT                                no effect on complex formation with gamma
FT                                subunit). {ECO:0000269|PubMed:28087732}.
FT                                /FTId=VAR_078285.
FT   VARIANT     101    101       M -> V (in MRD42; dbSNP:rs869312825).
FT                                {ECO:0000269|PubMed:27108799}.
FT                                /FTId=VAR_076650.
FT   VARIANT     106    106       A -> T (in MRD42; decreases receptor-
FT                                driven G protein activation; decreases
FT                                complex formation with gamma subunit;
FT                                decreases trimer formation with alpha and
FT                                gamma subunit; no effect on protein
FT                                abundance).
FT                                {ECO:0000269|PubMed:28087732}.
FT                                /FTId=VAR_078286.
FT   VARIANT     118    118       D -> G (in MRD42; decreases receptor-
FT                                driven G protein activation; no effect on
FT                                protein abundance; no effect on complex
FT                                formation with gamma subunit; no effect
FT                                on trimer formation with alpha and gamma
FT                                subunits). {ECO:0000269|PubMed:27668284,
FT                                ECO:0000269|PubMed:28087732}.
FT                                /FTId=VAR_078287.
FT   VARIANT     326    326       A -> T (in MRD42; dbSNP:rs869312826).
FT                                {ECO:0000269|PubMed:27108799}.
FT                                /FTId=VAR_076651.
FT   VARIANT     337    337       K -> Q (in MRD42; unknown pathological
FT                                significance; no effect on protein
FT                                abundance; no effect on complex formation
FT                                with gamma subunit; no effect on trimer
FT                                formation with alpha and gamma subunits;
FT                                no effect on receptor-driven G protein
FT                                activation).
FT                                {ECO:0000269|PubMed:28087732}.
FT                                /FTId=VAR_078288.
FT   HELIX         3     24       {ECO:0000244|PDB:5UKL}.
FT   HELIX        30     34       {ECO:0000244|PDB:5UKL}.
FT   STRAND       35     37       {ECO:0000244|PDB:4PNK}.
FT   STRAND       46     51       {ECO:0000244|PDB:5UKL}.
FT   STRAND       58     63       {ECO:0000244|PDB:5UKL}.
FT   STRAND       67     74       {ECO:0000244|PDB:5UKL}.
FT   STRAND       77     83       {ECO:0000244|PDB:5UKL}.
FT   TURN         84     86       {ECO:0000244|PDB:5UKL}.
FT   STRAND       89     94       {ECO:0000244|PDB:5UKL}.
FT   STRAND       96     98       {ECO:0000244|PDB:4PNK}.
FT   STRAND      100    105       {ECO:0000244|PDB:5UKL}.
FT   STRAND      109    116       {ECO:0000244|PDB:5UKL}.
FT   STRAND      121    127       {ECO:0000244|PDB:5UKL}.
FT   STRAND      129    131       {ECO:0000244|PDB:5UKL}.
FT   STRAND      134    139       {ECO:0000244|PDB:5UKL}.
FT   STRAND      146    153       {ECO:0000244|PDB:5UKL}.
FT   STRAND      156    161       {ECO:0000244|PDB:5UKL}.
FT   STRAND      166    170       {ECO:0000244|PDB:5UKL}.
FT   TURN        171    174       {ECO:0000244|PDB:5UKL}.
FT   STRAND      175    180       {ECO:0000244|PDB:5UKL}.
FT   STRAND      187    192       {ECO:0000244|PDB:5UKL}.
FT   STRAND      196    203       {ECO:0000244|PDB:5UKL}.
FT   STRAND      208    212       {ECO:0000244|PDB:5UKL}.
FT   TURN        213    215       {ECO:0000244|PDB:5UKL}.
FT   STRAND      218    222       {ECO:0000244|PDB:5UKL}.
FT   STRAND      229    234       {ECO:0000244|PDB:5UKL}.
FT   STRAND      238    245       {ECO:0000244|PDB:5UKL}.
FT   STRAND      250    254       {ECO:0000244|PDB:5UKL}.
FT   TURN        255    258       {ECO:0000244|PDB:5UKL}.
FT   STRAND      259    264       {ECO:0000244|PDB:5UKL}.
FT   STRAND      273    278       {ECO:0000244|PDB:5UKL}.
FT   STRAND      282    289       {ECO:0000244|PDB:5UKL}.
FT   STRAND      294    298       {ECO:0000244|PDB:5UKL}.
FT   TURN        299    301       {ECO:0000244|PDB:5UKL}.
FT   STRAND      304    308       {ECO:0000244|PDB:5UKL}.
FT   STRAND      315    320       {ECO:0000244|PDB:5UKL}.
FT   STRAND      327    331       {ECO:0000244|PDB:5UKL}.
FT   STRAND      336    340       {ECO:0000244|PDB:5UKL}.
SQ   SEQUENCE   340 AA;  37377 MW;  896CBD32D2686598 CRC64;
     MSELDQLRQE AEQLKNQIRD ARKACADATL SQITNNIDPV GRIQMRTRRT LRGHLAKIYA
     MHWGTDSRLL VSASQDGKLI IWDSYTTNKV HAIPLRSSWV MTCAYAPSGN YVACGGLDNI
     CSIYNLKTRE GNVRVSRELA GHTGYLSCCR FLDDNQIVTS SGDTTCALWD IETGQQTTTF
     TGHTGDVMSL SLAPDTRLFV SGACDASAKL WDVREGMCRQ TFTGHESDIN AICFFPNGNA
     FATGSDDATC RLFDLRADQE LMTYSHDNII CGITSVSFSK SGRLLLAGYD DFNCNVWDAL
     KADRAGVLAG HDNRVSCLGV TDDGMAVATG SWDSFLKIWN
//
